The immune checkpoint inhibitors PD-1 and PD-L1 (Nivolumab, Pembrolizumab, and Atezolizumab) are part of the treatment for NSCLC, both as monotherapy and in combination with CT in early and advanced stages. This evidence concerns the gene CD274 and non-small cell lung carcinoma.